Tirzepatide is a long-acting agonist of glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptors that results in 12 to 21% weight loss in patients with obesity; however ...

1 Section of General Internal Medicine, Department of Internal Medicine, Yale School of Medicine, New Haven, CT 2 Department of Health Policy and Management, Yale School of Public Health ...

Our family fishes commercially in New England, where we grow or catch a substantial portion of our food. About 15 years ago, my children and I began capturing bushels of European green crabs for ...

New England Business Media ... a daily update of the area’s most important business news. Worcester Business Journal provides the top coverage of news, trends, data, politics and personalities ...

The U.S. Food and Drug Administration (FDA) approved Journavx (suzetrigine) oral tablets on Thursday as a first-in-class ...

CagriSema, which underperformed expectations in its first Phase 3 test, will be studied at different doses and for longer ...

Ben Fischer of Sports Business Journal recently explained that the league has kept ... And same thing when we got good at Cleveland and then at New England. I mean, it’s [Tom] Brady, it’s [Willie] ...

Saint Louis University's School of Medicine has a long tradition of excellence in medical school, graduate medical education and graduate education. Established in 1836, the school has the distinction ...

With a new hand at the helm, the good ship Ireland is sailing successfully again. Off in search of treasure Simon Easterby’s side embarked with victory over England; there is plenty that must be ...

The left-back is a strong passer, which may work well with Tuchel's desire to maintain high volumes of possession, and leans more towards attack than defence which would allow England's new boss ...

On Monday, he thanked the firefighters who rescued him. By Katherine Rosman New York lawmakers may give Gov. Kathy Hochul more time to schedule special elections, a move backed by the House ...

Novo Nordisk defended its next-generation obesity drug candidate CagriSema on Wednesday following late-stage trial data published in December that disappointed investors and wiped $125 billion from ...